Case Studies

Biosimilars of novel targeted molecules play a crucial role in ensuring desirable treatment outcomes with a major benefit for larger masses, particularly in developing countries like India. They greatly reduce the cost of treatment without compromising the efficacy or safety of the treatment.

COVID 19 was a global crisis unlike any seen in modern times. The virus created havoc across the entire world with healthcare responders struggling to find the right treatment owing to the novel nature of the virus. There was a need for identifying and developing an effetive treatment for the management of the disease.

Despite global consensus on treatments for metastatic colorectal cancer targeting different mutations like EGFR, VEGF, and HER2, the Indian context lacks clarity. The client, large sized Indian pharma, wanted to help establish the same in India which is capture in the case study below.

X
Scroll to Top